Statistical Issues in the Analysis of Patient Outcomes April 11, 2003 Elizabeth Garrett Oncology Biostatistics Acknowledgement: Thanks to Ron Brookmeyer.

Slides:



Advertisements
Similar presentations
The analysis of survival data in nephrology. Basic concepts and methods of Cox regression Paul C. van Dijk 1-2, Kitty J. Jager 1, Aeilko H. Zwinderman.
Advertisements

1 QOL in oncology clinical trials: Now that we have the data what do we do?
Introduction to Survival Analysis October 19, 2004 Brian F. Gage, MD, MSc with thanks to Bing Ho, MD, MPH Division of General Medical Sciences.
1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.
Departments of Medicine and Biostatistics
Observational Studies Based on Rosenbaum (2002) David Madigan Rosenbaum, P.R. (2002). Observational Studies (2 nd edition). Springer.
Lecture 6: Repeated Measures Analyses Elizabeth Garrett Child Psychiatry Research Methods Lecture Series.
April 25 Exam April 27 (bring calculator with exp) Cox-Regression
From last time….. Basic Biostats Topics Summary Statistics –mean, median, mode –standard deviation, standard error Confidence Intervals Hypothesis Tests.
Model and Variable Selections for Personalized Medicine Lu Tian (Northwestern University) Hajime Uno (Kitasato University) Tianxi Cai, Els Goetghebeur,
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Clustered or Multilevel Data
Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.
Quality of Life Assessment in Clinical Trials Adapted from Introduction to Clinical Trials Biostatistics.
Dr K N Prasad MD., DNB Community Medicine
Assessing Survival: Cox Proportional Hazards Model Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Analysis of Complex Survey Data
As noted by Gary H. Lyman (JCO, 2012) “CER is an important framework for systematically identifying and summarizing the totality of evidence on the effectiveness,
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 12: Multiple and Logistic Regression Marshall University.
Survival analysis Brian Healy, PhD. Previous classes Regression Regression –Linear regression –Multiple regression –Logistic regression.
Statistical Issues in Data Collection and Study Design For Community Programs and Research October 11, 2001 Elizabeth Garrett Division of Biostatistics.
Analysis Issues in Assessing Efficacy in Randomized Clinical Trials “Intention to Treat” and Compliance Elizabeth Garrett-Mayer Oncology Biostatistics.
Multiple Choice Questions for discussion
Evidence-Based Medicine 4 More Knowledge and Skills for Critical Reading Karen E. Schetzina, MD, MPH.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
The Diabetic Retinopathy Clinical Research Network 5-Year Follow-up of a Randomized Trial Evaluating Ranibizumab Plus Prompt versus Deferred Laser for.
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
1 Introduction to medical survival analysis John Pearson Biostatistics consultant University of Otago Canterbury 7 October 2008.
Assessing Survival: Cox Proportional Hazards Model
Article Review Cara Carty 09-Mar-06. “Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of.
Multilevel Data in Outcomes Research Types of multilevel data common in outcomes research Random versus fixed effects Statistical Model Choices “Shrinkage.
INTRODUCTION TO SURVIVAL ANALYSIS
CS 478 – Tools for Machine Learning and Data Mining Linear and Logistic Regression (Adapted from various sources) (e.g., Luiz Pessoa PY 206 class at Brown.
Linear correlation and linear regression + summary of tests
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
1 1 Using Marginal Structural Model to Estimate and Adjust for Causal Effect of Post- discontinuation Chemotherapy on Survival in Cancer Trials Y. Wang,
April 4 Logistic Regression –Lee Chapter 9 –Cody and Smith 9:F.
HSRP 734: Advanced Statistical Methods July 31, 2008.
Assessing Binary Outcomes: Logistic Regression Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Osteoarthritis Initiative Analytic Strategies for the OAI Data December 6, 2007 Charles E. McCulloch, Division of Biostatistics, Dept of Epidemiology and.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Three Statistical Issues (1) Observational Study (2) Multiple Comparisons (3) Censoring Definitions.
Survival Analysis 1 Always be contented, be grateful, be understanding and be compassionate.
Lecture 12: Cox Proportional Hazards Model
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Evaluating Risk Adjustment Models Andy Bindman MD Department of Medicine, Epidemiology and Biostatistics.
1 Multivariable Modeling. 2 nAdjustment by statistical model for the relationships of predictors to the outcome. nRepresents the frequency or magnitude.
Satistics 2621 Statistics 262: Intermediate Biostatistics Jonathan Taylor and Kristin Cobb April 20, 2004: Introduction to Survival Analysis.
Using Propensity Score Matching in Observational Services Research Neal Wallace, Ph.D. Portland State University February
Biostatistics Case Studies 2014 Youngju Pak Biostatistician Session 5: Survival Analysis Fundamentals.
1 Statistics 262: Intermediate Biostatistics Regression Models for longitudinal data: Mixed Models.
Can patients be satisfied to death? What was Joshua J. Fenton thinking? Ron D. Hays, Ph.D. July 21, 2015 UCLA Center for Maximizing Outcomes and Research.
Instrument design Essential concept behind the design Bandit Thinkhamrop, Ph.D.(Statistics) Department of Biostatistics and Demography Faculty of Public.
Armando Teixeira-Pinto AcademyHealth, Orlando ‘07 Analysis of Non-commensurate Outcomes.
INTRODUCTION TO CLINICAL RESEARCH Survival Analysis – Getting Started Karen Bandeen-Roche, Ph.D. July 20, 2010.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
1 Statistics 262: Intermediate Biostatistics Mixed models; Modeling change.
Zometa for Prostate Cancer Bone Metastases Protocol 039 Amna Ibrahim, M.D. Oncology Drug Products FDA.
Approaches to quantitative data analysis Lara Traeger, PhD Methods in Supportive Oncology Research.
REGRESSION MODEL FITTING & IDENTIFICATION OF PROGNOSTIC FACTORS BISMA FAROOQI.
Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer Bryan P. Schneider,
Meta-analysis of observational studies Nicole Vogelzangs Department of Psychiatry & EMGO + institute.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 13: Multiple, Logistic and Proportional Hazards Regression.
SURVIVAL ANALYSIS PRESENTED BY: DR SANJAYA KUMAR SAHOO PGT,AIIH&PH,KOLKATA.
Measures of disease frequency Simon Thornley. Measures of Effect and Disease Frequency Aims – To define and describe the uses of common epidemiological.
RTI International RTI International is a trade name of Research Triangle Institute. Selecting Endpoints for Clinical Trials.
Sample size calculation Ahmed Hassouna, MD
NAPLEX preparation: Biostatistics
Jeffrey E. Korte, PhD BMTRY 747: Foundations of Epidemiology II
Presentation transcript:

Statistical Issues in the Analysis of Patient Outcomes April 11, 2003 Elizabeth Garrett Oncology Biostatistics Acknowledgement: Thanks to Ron Brookmeyer for providing lecture notes from previous years, which I have adapted into powerpoint.

Factors of Interest in Outcomes Research How do we measure…. –Treatment effects? –Access to care? –Quality of care? –Continuity of care? Other variables of interest –Demographic/baseline patient characteristics –Type of provider –Etc……

Critical Statistical Issues in Patient Outcome Data NOT RANDOMIZED LONGITUDINAL

Properties of Randomized Trials Random assignment (Double) blind Defined treatment protocol Patient Eligibility RANDOMIZE AB

BIAS Randomization controls bias Potential Biases in non-randomized studies –Physician selects treatment –Patient self-selects treatment –Those in A are probably not ‘like’ those in B –Example: prostate cancer study of men after prostatectomy Patients who received hormonal therapy were more likely to relapse than those who didn’t Why? Study was a retrospective study of patient records. Patients at high risk of relapse were more likely to be given hormonal therapy CONFOUNDING Generalizability of results in non-randomized trial?

Randomized versus Other Controls Historical Controls Matched/Selected Controls Example: Pooled Estimates of overall survival in clinical trials of medical versus surgical treatment of coronary artery disease “Adjusted”: adjusted to have same proportion with one-, two- and three- vessel disease as the randomized trials. Number of Studies Number of Patients 1 year survival rate Randomized trials Surgical92.4 Medical93.4 Historical Trials99290 Surgical93.0 Medical83.8 Surgical Adjusted 93.7 Medical Adjusted 88.2

Statistical Adjustment Will not always work! You need to –Know what to adjust for –Have available the adjustment variables –Know the functional form for the adjustment

Statistical Analysis and Adjustment Goal: Control for imbalance Outcome data: –Binary (proportions): e.g., cure rate, relapse, death –Continuous: e.g. quality of life, length of stay, cost –Survival time: e.g. time to death, time to discharge –Longitudinal data: e.g.change in quality of life –Multiple outcomes: Competing risks: e.g. procedure puts you at risk of death, but if successful, procedure cures disease. Multivariate outcome: e.g. latent variable which is measured by several variables, such as quality of life, functional status, etc.

Adjustment for Binary Outcomes Unadjusted analysis: Compare proportions that improve in groups A and B Fisher’s exact test Confounding? –Maybe all those in A had a better prognosis to begin with….. AB Yes2515 No Treatment Improve 63% improvement on A 38% improvement on B Pvalue = 0.04

Prenatal Care and Fetal Mortality Low CareHigh Care Died46 (11%)20 (6%) Survived Low CareHigh Care Died12 (6.4%)16 (5.5%) Survived Mortality rates: 11% in low care 6% in high care pvalue = 0.02 Low CareHigh Care Died34 (17.3%)4 (17.4%) Survived Provider 1Provider 2 pvalue = 0.56 pvalue = 1.00

Prenatal Care and Fetal Mortality Prenatal care is not associated with mortality Provider is a confounder –Mortality rates are lower in provider 1 than in provider 2. –Distribution of care is different in providers 1 and 2 (62% high care in provider 1 and only 10% in provider 2) Low CareHigh Care Died12 (6.4%)16 (5.5%) Survived Low CareHigh Care Died34 (17.3%)4 (17.4%) Survived Provider 1Provider 2 pvalue = 0.56 pvalue = 1.00

Confounding review care mortality ? provider

How to adjust We can’t always stratify –Sparseness –What about continuous variables? Solution: regression methods

Logistic regression For binary outcomes Outcome: p i = probability of death of infant i Covariates: x 1i = 1 if infant i is in high care, 0 if low care x 2 = 1 if infant i is in high care provider 2, 0 if provider 1 Example:  1 = 0.15, std error = 0.33 e  1 = 1.16 Z = 0.15/0.33 = 0.45 pvalue > 0.5 After controlling for provider, level of care is not associated with mortality

Linear Regression Example: Work days missed among patients with asthma Outcome: y i = number of days missed by patient i Covariates: –x 1i = 1 if patient i uses steroid inhaler, 0 if not –x 2i = asthma severity of patient i Results:  1 = 3.0, std error = 0.60 Those with inhalers lose, on average, 3 more days of work, controlling for severity.

Interactions What if effect of inhaler varies by severity? Assume only two levels of severity for simplicity. x 1 x 2 = interaction between severity and inhaler Interpretation: –  1 is the number of days due to inhaler in patients with low severity –  1 +  3 i s the number of days due to inhaler in patients with high severity

Regression for survival outcomes Cox proportional hazards model –Time to event outcome –Allows for ‘censoring’ (i.e. incomplete follow-up) h(t) = hazard or incidence rate Example: mental health –Time to next inpatient visit

Time to inpatient visit Looking at patients on treatment A versus treatment B for schizophrenia. Relative risk = rate ratio = 2 Patients on treatment B are at twice the risk of inpatient visit compared to those on A. A B Could it be that those on B already failed on treatment A? That would make them ‘worse prognosis’ patients.

Longitudinal Analysis Repeated observations on the same patient over time Example: physical well-being score Random effects model: –Linear regression setting –Each patient has his own intercept –i indexes patients, j indexes time

Compare slopes Treatment A: slopes = 1 Treatment B: slopes = 2

Longitudinal (continued) In addition to modeling over time, can include adjustments for confounders. SAS proc mixed, Stata (xtreg) Generalized Estimating Equations –Liang and Zeger –Accounts for correlation –Can use for continuous or binary data LDA class offered 3 rd term (Dr. Dominici)

Quality of Life Data Often interested in whether or not survival with poor quality of life is better than death without suffering. “QALY”= Quality Adjusted Years of Life Example: –Cancer: many patients would rather not get toxic therapies and have more enjoyable end of life The general idea is to down-weight time spent in periods of poor quality of life. Methodologically challenging: –How to determine the weights? –Different settings might need different weights.

Quality Adjusted Survival QTWIST: Quality-Adjusted Time Without Symptoms of disease and Toxicity. Evaluate therapies based on both quantity and quality of life through survival analysis Based on QALYs. –Define QOL health states, including one with good health (minimal symptoms). –Patients progress through health states and never back-track. –Partition the area under the Kaplan-Meier Curve and calculate the average time spent in each clinical health state. –Compare treatment regimens using weighted sums durations, weights are utility based. Example: 5 year survival 3 adjusted years of life Compare the average QTWIST in two treatment groups. Could be that on treatment A, people live longer, but QOL is worse. Quality of Life for Individual

Multiple Outcome Measures Multiple instruments or subscales Examples: –Physical functioning –General health –Mental health –Pain –Social functioning “Latent variables” Approaches –“STA”: Summarize then analyze –“ATS”: Analyze then summarize –“SAA”: Summarize and analyze

Summarize then Analyze Choose a summary score for your outcome variable –E.g. the total number of depression symptoms –E.g. the average pain score over the previous week –E.g. the sum of the individual physical function items Treat this summary score as “observed” Proceed with analysis (e.g. look for treatment differences) Pros: easy to understand, face validity Con: ignores measurement error, might not be a valid or efficient measure.

Analyze then Summarize Analyze each item in the scale separately Example: How is treatment related to –Pain on day 1? –Pain on day 2? –Pain on day 3? –….. Qualitatively summarize the results. Pros: considers that the items are each different (i.e. issue of “exchangeability”) Cons: Summarizing can be difficult especially if associations are in different directions; no “number” at the end of the analysis to quantify the association or its significance.

Structural Equation Models “path models” Uses ‘factor analysis’ approach to summarize variables (i.e. measurement model) and create latent variables Uses regression techniques to associate other variables with latent variable

Do both in one model. “Structural Equation Models” Summarize and Analyze Simultaneously X   Y1Y1 Y2Y2 YmYm 11 mm 22 11 22 mm Assume variable of interest is general health status (  ). The Y variables are indicators of general health. We want to see how treatment is associated with general health status.

Summary Main statistical issue is outcomes research: LACK OF RANDOMIZATION –Bias introduced –Needs adjustment Regression methods can be used to adjust –Binary: logistic –Continuous: linear –Survival: Cox proportional hazards –Longitudinal: random effects, GEE Quality of Life –QALYs –QTWiST Multiple measures and latent variables

References Longitudinal: Diggle, Liang, and Zeger Survival Analysis: Collett Quality of Life: see handout from Fairclough and Gelber Thanks (again) to R. Brookmeyer for his handouts and examples from previous lectures.